Annual General Shareholders' Meeting of May 10, 2017
- Shareholders' approval of the financial statements for 2016 -
- Dividend of €2.96 per share payable as of May 18, 2017 -
- Board Composition: renewal and appointments -
Paris, France - May 10, 2017 - The Combined General Shareholders' Meeting of Sanofi was held today at the Palais des Congrès in Paris under the chairmanship of Serge Weinberg. All resolutions submitted to the vote were adopted by its shareholders.
The shareholders approved, among other resolutions, the individual Company and consolidated financial statements for the year 2016. At the General Meeting, shareholders decided the distribution of a cash dividend in the amount of € 2.96 per share with payment as of May 18, 2017.
The General Meeting also renewed as Director Fabienne Lecorvaisier and approved the appointment of Bernard Charlès and Melanie Lee as independent Directors, for a term of four years, i.e., until the General Meeting called to approve the financial statements for the year 2020.
Following the General Meeting, the new Board of Directors is comprised of 14 members, of whom six are women. A large majority of the Board's Directors is independent
- Serge Weinberg*, Chairman of the Board of Directors
- Olivier Brandicourt, Chief Executive Officer
- Laurent Attal
- Robert Castaigne*
- Bernard Charlès*
- Claudie Haigneré*
- Patrick Kron*
- Fabienne Lecorvaisier*
- Melanie Lee*
- Suet-Fern Lee*
- Christian Mulliez
- Carole Piwnica*
- Diane Souza*
- Thomas Südhof*
The composition of the committees remains unchanged.
The voting results will be available on the Company's website (www.sanofi.com) in the coming days.
The audiocast of the Annual General Shareholder Meeting is available on the Company's website (www.sanofi.com).
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Contacts:
| Relations Presse Laurence Bollack + (33) 1 53 77 46 46 [email protected] | Relations Investisseurs George Grofik + (33) 1 53 77 45 45 [email protected] |
(* Independent Director)
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/51edbdd2-14e5-4db4-9da7-c2241639ea4c


Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook
Samsung Set to Begin HBM4 Production for Nvidia and AMD 



